Linked Life Data

19479457

Source:http://linkedlifedata.com/resource/pubmed/id/19479457

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-1-19
pubmed:abstractText
Our results indicate that repeated treatment courses with tobramycin 10 mg/kg (twice daily for 3 weeks) may be safely applied in cystic fibrosis (CF) patients with respect to ototoxicity. The risk of hearing loss in this patient group is less than expected, which could be explained by either unfavourable baseline audiometry or the use of unidentified protective medication, or both. However, due to large inter-individual variations, audiometry screening remains important with respect to the detection of individual outliers.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1651-2251
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
130
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
253-8
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
No hearing loss after repeated courses of tobramycin in cystic fibrosis patients.
pubmed:affiliation
Department of Otorhinolaryngology, Head and Neck Surgery, The Netherlands Cancer Institute, 1066 CXAmsterdam, The Netherlands. r.scheenstra@nki.nl
pubmed:publicationType
Journal Article